Boehringer Ingelheim’s (BI) adalimumab biosimilar, Cyltezo, can be successfully self-administered—via auto-injector—by most patients with rheumatoid arthritis (RA).
Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo, which is approved though not yet launched in the United States and European Union, can be successfully self-administered—via auto-injector—by most patients with rheumatoid arthritis (RA).
That finding derives from a newly published paper in Expert Opinion that assessed real-life patient handling and self-injection of the biosimilar using the auto-injector device. The study, reported on by a research team led by Stanley Cohen, MD, included adult patients (aged 18 to 80 years) with moderate to severe rheumatoid arthritis (RA) at 19 sites in Poland and the United States.
The 7-week, phase 2, open-label, single-arm, interventional clinical trial in which patients self-injected 3 subcutaneous doses of the biosimilar with an auto-injector after having received training on how to use the device and having self-administered 1 training injection.
The injector device is pressed against the skin at a 90-degree angle, the user pushes an injection button confirmed by a clicking sound, and the duration of injection is approximately 10 seconds. Completion of the injection can be confirmed by inspecting the plunger in a viewer window. Injections were considered successful if the full content of the device was injected into the body.
In total, 77 patients were included in the study and completed 218 self-injections. Of those injections, 216 (99.1%) were successful as reported by both site personnel and patients. In the 2 cases of unsuccessful injections, the reported cause was that the device’s button could not be depressed by the patient. As no technical issues were identified with the device, the failure was deemed to be user error in both cases. The 2 patients with failed attempts were able to successfully administer a second injection.
The study’s authors say that, as the auto-injector presentation of the biosimilar is easy to use, there may be less unintentional nonadherence among patients receiving therapy with the biosimilar.
Reference
Cohen S, Klimiuk PA, Krahnke T, Assudani D. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE-RL). [Published online May 15, 2018.] Expert Opinion. doi: 10.1080/17425247.2018.1472572.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.